entacapone (Comtan)

Subscribe to Selected New Research on entacapone

157 relevant articles (22 outcomes, 40 trials/studies) found for this Drug

Description: structure given in first source

Also Known As:

Comtan; 2-cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide; Comtess; Novartis brand of entacapone; OR 611; OR-611; Orion brand of entacapone; (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Experts

1.	Gordin, A: 6 articles (03/2003 - 05/2000)
2.	Brooks, D J: 4 articles (01/2005 - 04/2000)
3.	Bourdeix, I: 3 articles (07/2008 - 01/2001)
4.	Guarnieri, M: 3 articles (04/2005 - 10/2004)
5.	Hubble, J: 3 articles (04/2005 - 10/2004)
6.	Leinonen, M: 3 articles (03/2003 - 01/2001)
7.	Erdmann, Christoph: 2 articles (07/2008 - 05/2007)
8.	Woitalla, Dirk: 2 articles (07/2008 - 05/2007)
9.	Müller, Thomas: 2 articles (07/2008 - 05/2007)
10.	Brooks, David J: 2 articles (06/2008 - 02/2008)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 08/01/2003 - "Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study." 10/01/2004 - "Significant improvement with entacapone treatment was detected in several quality-of-life measures, including the Parkinson Disease Questionnaire 39, the 36-item Short-Form Health Survey, the Parkinson's Symptom Inventory, and investigator and subject Clinical Global Assessments" 07/01/2001 - "CONCLUSION: The study shows that entacapone is a cost-effective treatment in patients with Parkinson's disease: entacapone yields higher effectiveness in terms of both effectiveness measures (time without severe fluctuations and QALYs), while costs remain quite similar to those for usual care" 03/01/2007 - "Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention." 08/01/2004 - "The efficacy of entacapone and its impact on patient quality of life (QOL) was investigated in an open-label study of 899 patients with idiopathic Parkinson's Disease (PD) experiencing wearing-off fluctuations" Get all the results and reference details, order at left...
2.	Dyskinesias (Dyskinesia) 08/01/1999 - "In these and other phase III studies, entacapone was generally well tolerated, with most adverse effects being dyskinesias and gastrointestinal disorders" 04/16/1999 - "In these and other phase III studies, entacapone was generally well tolerated, with few reported adverse events, mainly dyskinesias and gastrointestinal disorders" 01/01/2007 - "Adverse events occurred in 79 patients (69.9%) in placebo, 82 (72.6%) in 100 mg, and 98 (86.0%) in 200 mg. The most common adverse event with entacapone was an increase in dyskinesias" 05/01/2004 - "Advanced disease stage, presence of cognitive dysfunction, and presence of dyskinesia should not necessarily preclude patients from being treated with entacapone, when otherwise indicated." 01/01/2001 - "As expected, due to dopaminergic enhancement, dyskinesia was more frequent as an AE with entacapone than with placebo" Get all the results and reference details, order at left...
3.	Hyperhomocysteinemia 12/01/2007 - "This hyperhomocysteinemia could be prevented by entacapone but not folate co-administration." 04/24/2007 - "Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study." 06/27/2006 - "Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study." 12/01/2007 - "BACKGROUND: This study investigated whether brief exposure to nitrous oxide (N(2)O) exacerbates levodopa-induced hyperhomocysteinemia, and if co-treatment with folate or entacapone could reduce total plasma homocysteine (tHcy) levels" Get all the results and reference details, order at left...
4.	Nausea 07/01/1999 - "Dopaminergic events, including dyskinesia and nausea, are among the most common events with entacapone, and are related to the drug's ability to potentiate the effects of levodopa" 04/01/2002 - "Increased dyskinesias (entacapone 34%, placebo 26%) and nausea (10 and 5%, respectively), mostly occurring shortly after treatment initiation, were generally managed by reducing the levodopa dose" 02/01/2008 - "These trials have also shown that levodopa/DDCI and entacapone is generally well tolerated, with notable adverse events including worsening dyskinesia, nausea and diarrhea" Get all the results and reference details, order at left...
5.	Parkinsonian Disorders (Parkinsonism) 11/01/1997 - "Entacapone is effective at increasing the duration of response to levodopa and at relieving parkinsonism in patients experiencing motor fluctuations and was well tolerated during the 24 weeks of treatment." 12/01/2006 - "The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full-time-employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self-perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias" Get all the results and reference details, order at left...
31 Diseases and 157 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Carbidopa (Lodosyn)
3.	Stalevo
4.	Dopa Decarboxylase
5.	tolcapone (Tasmar)
6.	ropinirole (Requip)
7.	Complement System Proteins (Complement)
8.	Catechol O-Methyltransferase (Methyltransferase, Catechol)
9.	Dopamine Agonists (Dopamine Agonist)
10.	Vitamins
186 Drugs and Important Bio-Agents and 135 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Activities of Daily Living (ADL)
2.	Stents
3.	Aftercare (After-Treatment)
3 Therapies and Procedures and 4 more articles analyzed in the Research Interface, order at left...

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>